An investigation was done on plausible antibody treatments for alpha-synuclein, which is an instigator for the dopamine-lacking neurodegenerative disease Parkinson’s to occur in patients due to its aggregation. Trials working towards slowing the pathogenesis of Parkinson’s Disease through monoclonal antibodies for alpha-synuclein were analyzed. Previously, similar therapies were done in other neurodegenerative diseases like Alzheimer’s, allowing for a hopeful hypothesis in Parkinson’s. Active and Passive antibody treatments were compared and discussed: Pranizeumab, Cipanemab, PD01A, and UB-312. Trials often found success in animal models and not the same outcome in humans within the passive studies. In active studies, however, more hopeful results were presented, showing built immunity towards alpha-synuclein and enhancement of motor symptoms. Though some studies led to a dead end, studies use information to complete future phases. Monoclonal antibody treatment for Parkinson’s Disease is a real future in the fight for reducing the pathogenesis of Parkinson’s Disease.
No takes yet. Share an insight, caveat, or question.
Jain et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: